BMS-37

• Description :

  BMS-37 is a PD-1/PD-L1 immune checkpoint inhibitor with an IC50 towards the PD-L1/PD-1 complex in the range of 18 to 200 nM. BMS-37 shows unspecific toxicity against modified Jurkat T cells with an EC50 between 3 and 6 µM. BMS-37 can be used for the study of the PD-L1-induced exhaustion of T-cells or as PD-L1 ligand to synthesize PROTAC molecules[1][2][3].

• CAS Number :

  [1675202-20-6]

• UNSPSC :

  12352005

• Target :

  Ligands for Target Protein for PROTAC; PD-1/PD-L1

• Type :

  Reference compound

• Related Pathways :

  Immunology/Inflammation; PROTAC

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/bms-37.html

• Purity :

  98.01

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  COC1=CC(OCC2=CC=CC(C3=CC=CC=C3)=C2C)=CC(OC)=C1CNCCNC(C)=O

• Molecular Formula :

  C27H32N2O4

• Molecular Weight :

  448.55

• References & Citations :

  [1]Yang L, et, al. Design, synthesis, and evaluation of PD-L1 degraders to enhance T cell killing activity against melanoma. Chinese Chemical Letters. 2022 Aug 20: 107762.|[2]Zak KM, et al. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1) . Oncotarget. 2016 May 24;7 (21) :30323-35.|[3]Skalniak L, et al. Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells. Oncotarget. 2017 Aug 7;8 (42) :72167-72181.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported